The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: a meta-analysis of randomized, controlled trials
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
Amado, R. G., Wolf, M., Peeters, M., Van Cutsem, E., Siena, S., Freeman, D. J., Juan, T., Sikorski, R., Suggs, S., Radinsky, R., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.7116 · Cited by 3,207 · cited 2×
“Anti-EGFR mAb third-line monotherapy (based on a single study [10, 19]) was estimated to have significantly greater benefit than first-/second-line anti-EGFR mAb therapy in combination with chemotherapy with respect to PFS (P = 0.”
BackgroundPanitumumab–FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer
Douillard, J.-Y., Oliner, K. S., Siena, S., Tabernero, J., Burkes, R., Barugel, M., Humblet, Y., Bodoky, G., Cunningham, D., Jassem, J., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305275 · Cited by 2,263
Cetuximab for the Treatment of Colorectal Cancer
Jonker, D. J., O'Callaghan, C. J., Karapetis, C. S., Zalcberg, J. R., Tu, D., Au, H.-J., Berry, S. R., Krahn, M., Price, T., Simes, R. J., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa071834 · Cited by 1,904
Self-citationCetuximab in the treatment of colorectal cancer.
Goldberg, R. M., Venook, A. P., & Schilsky, R. L. (2004) · PubMed · Cited by 1,518
Maughan, T. S., Adams, R. A., Smith, C. G., Meade, A. M., Seymour, M. T., Wilson, R. H., Idziaszczyk, S., Harris, R., Fisher, D., Kenny, S. L., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60613-2 · Cited by 960
Sobrero, A. F., Maurel, J., Fehrenbacher, L., Scheithauer, W., Abubakr, Y. A., Lutz, M. P., Vega-Villegas, M. E., Eng, C., Steinhauer, E. U., Prausova, J., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.1193 · Cited by 946
Sartore-Bianchi, A., Martini, M., Molinari, F., Veronese, S., Nichelatti, M., Artale, S., Di Nicolantonio, F., Saletti, P., De Dosso, S., Mazzucchelli, L., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2466 · Cited by 739
Schwartzberg, L. S., Rivera, F., Karthaus, M., Fasola, G., Canon, J.-L., Hecht, J. R., Yu, H., Oliner, K. S., & Go, W. Y. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.53.2473 · Cited by 635
Roock, W. D., Vriendt, V. D., Normanno, N., Ciardiello, F., & Tejpar, S. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70209-6 · Cited by 603
Tveit, K. M., Guren, T., Glimelius, B., Pfeiffer, P., Sorbye, H., Pyrhonen, S., Sigurdsson, F., Kure, E., Ikdahl, T., Skovlund, E., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.0915 · Cited by 533
Venook, A. P., Niedzwiecki, D., Lenz, H.-J., Innocenti, F., Mahoney, M. R., O'Neil, B. H., Shaw, J. E., Polite, B. N., Hochster, H. S., Atkins, J. N., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.32.15_suppl.lba3 · Cited by 428
Seymour, M. T., Brown, S. R., Middleton, G., Maughan, T., Richman, S., Gwyther, S., Lowe, C., Seligmann, J. F., Wadsley, J., Maisey, N., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70163-3 · Cited by 388
Peeters, M., Douillard, J.-Y., Van Cutsem, E., Siena, S., Zhang, K., Williams, R., & Wiezorek, J. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.1492 · Cited by 232
Dahabreh, I. J., Terasawa, T., Castaldi, P. J., & Trikalinos, T. A. (2011) · Annals of Internal Medicine · doi:10.7326/0003-4819-154-1-201101040-00006 · Cited by 172
Vale, C. L., Tierney, J. F., Fisher, D. J., Adams, R., Kaplan, R. S., Maughan, T., Parmar, M., & Meade, A. M. (2011) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2011.11.002 · Cited by 115
Cost-Effectiveness Analysis of Screening for KRAS and BRAF Mutations in Metastatic Colorectal Cancer
Behl, A. S., Goddard, K. A. B., Flottemesch, T. J., Veenstra, D. L., Meenan, R. T., Lin, J. S., & Maciosek, M. V. (2012) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djs433 · Cited by 101
Stintzing, S., Jung, A., Rossius, L., Modest, D. P., von Weikersthal, L. F., Decker, T. W., Kiani, A., Al‐Batran, S., Vehling‐Kaiser, U., Heintges, T., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.32.3_suppl.445 · Cited by 97
Bokemeyer, C., Köhne, C., Bondarenko, I., von Heydebreck, A., Grote, H. J., Stroh, C., & Lenz, H. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.31.15_suppl.3537 · Cited by 93
Jonker, D. J., Karapetis, C. S., Harbison, C. T., O'Callaghan, C. J., Tu, D., Simes, R. J., Malone, D. P., Langer, C., Tebbutt, N. C., Price, T. J., et al. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.753 · Cited by 87
Self-citationAdelstein, B., Dobbins, T., Harris, C. A., Marschner, I. C., & Ward, R. L. (2011) · European Journal of Cancer · doi:10.1016/j.ejca.2011.03.031 · Cited by 75
Explaining the Unexplainable: EGFR Antibodies in Colorectal Cancer
Grothey, A. A., & Lenz, H. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.40.4194 · Cited by 53
Patterson, S. D., Peeters, M., Siena, S., Cutsem, E. V., Humblet, Y., Laethem, J. V., André, T., Tian, Y., Sidhu, R., & Oliner, K. S. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.31.15_suppl.3617 · Cited by 43
Bokemeyer, C., Köhne, C., Ciardiello, F., Lenz, H., Heinemann, V., Klinkhardt, U., Beier, F., Duecker, K., & Tejpar, S. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.32.15_suppl.3505 · Cited by 42
Peeters, M., Oliner, K. S., Price, T. J., Cervantes, A. M. R., Sobrero, A. F., Ducreux, M. P., Hotko, Y., André, T., Chan, E. W., Lordick, F., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.32.3_suppl.lba387 · Cited by 40
Peeters, M., Oliner, K. S., Price, T. J., Cervantes, A. M. R., Sobrero, A. F., Ducreux, M. P., Hotko, Y., André, T., Chan, E. W., Lordick, F., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.32.15_suppl.3568 · Cited by 37
Ciardiello, F., Lenz, H., Köhne, C., Heinemann, V., Tejpar, S., Melezínek, I., Beier, F., Stroh, C., & Cutsem, E. V. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.32.15_suppl.3506 · Cited by 35
Cited by
ESMO consensus guidelines for the management of patients with metastatic colorectal cancer
Van Cutsem, E., Cervantes, A., Adam, R., Sobrero, A., Van Krieken, J. H., Aderka, D., Aranda Aguilar, E., Bardelli, A., Benson, A., Bodoky, G., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw235 · Cited by 3,421
Epidermal Growth Factor Receptor Cell Proliferation Signaling Pathways
Wee, P., & Wang, Z. (2017) · Cancers · doi:10.3390/cancers9050052 · Cited by 2,027
Colon Cancer, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology
Benson, A. B., Venook, A. P., Al-Hawary, M. M., Arain, M. A., Chen, Y.-J., Ciombor, K. K., Cohen, S., Cooper, H. S., Deming, D., Farkas, L., et al. (2021) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2021.0012 · Cited by 1,696
Colon Cancer, Version 1.2017, NCCN Clinical Practice Guidelines in Oncology
Benson, A. B., Venook, A. P., Cederquist, L., Chan, E., Chen, Y.-J., Cooper, H. S., Deming, D., Engstrom, P. F., Enzinger, P. C., Fichera, A., et al. (2017) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2017.0036 · Cited by 1,330
Mosele, F., Remon, J., Mateo, J., Westphalen, C. B., Barlesi, F., Lolkema, M. P., Normanno, N., Scarpa, A., Robson, M., Meric-Bernstam, F., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.07.014 · Cited by 1,186
Metadata
- Authors
- Sorich, M. J., Wiese, M. D., Rowland, A., Kichenadasse, G., McKinnon, R. A., & Karapetis, C. S.
- Venue
- Annals of Oncology
- Publisher
- Elsevier BV
- Published
- 2015-01
- Volume
- 26
- Issue
- 1
- Pages
- 13-21
- ISSN
- 0923-7534 (ISSN-L)
- OpenAlex
- W2121869934
- Cited by
- 540
- References
- 26
- FWCI
- 6.40
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.